Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer
CONCLUSIONS: We demonstrated that both the univariate and joint Bayesian models reduced uncertainty in predicting OS compared to frequentist method. The methodology introduced here will have potential applications in clinical decision-making for other oncology trials.PMID:38035666 | DOI:10.1080/13696998.2023.2272534
Source: Journal of Medical Economics - Category: Health Management Authors: Sory Traore Andreas Sashegyi Katherine B Winfree Kaisa-Leena Taipale Min-Hua Jen Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Economics | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva